Hua Medicine (Shanghai) Ltd. (SEHK: 2552)
Health Care · Pharmaceuticals · CN
HK$2.23
-4.90% today · -42.4% 1Y
Hua Medicine (Shanghai) Ltd. (SEHK: 2552) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $283.77M and employs 424 people.
Over the last twelve months the share price has lost 42.4%, trading between 1.97 and 4.57.
Tweenvest scores Hua Medicine (Shanghai) Ltd. across four factors: quality 51/100, value 93/100. Its strongest factor is value.
2552 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $283.77M
- Revenue (TTM)
- $96.34M
- P/E
- —
- EPS
- -0.11
- Dividend yield
- —
- Beta (5Y)
- 0.81
- 52-week high
- HK$4.57
- 52-week low
- HK$1.97
- Avg volume (3M)
- —
- Shares outstanding
- 998.63M
- Employees
- 424
- Next earnings
- —
About Hua Medicine (Shanghai) Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
- ISIN
- KYG4644K1022
- Founded
- 2011
- Listed since
- Sep 14, 2018
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| EyePoint, Inc.NasdaqGM: EYPT | $293.12M | $3.30 | -3.09% |
| BioAge Labs, Inc.NasdaqGS: BIOA | $290.99M | $5.94 | -6.31% |
| Lavipharm S.A.ATSE: LAVI | $288.74M | €1.51 | -3.70% |
| Fulcrum Therapeutics, Inc.NasdaqGM: FULC | $287.64M | $3.75 | -0.66% |
| Tiansheng Pharmaceutical Group Co., Ltd.SZSE: 002872 | $283.43M | CN¥5.97 | -3.55% |
| Starpharma Holdings LimitedASX: SPL | $282.89M | AU$0.85 | +5.62% |
| Antibiotice S.A.BVB: ATB | $281.52M | RON2.00 | +0.20% |
| Antengene Corporation LimitedSEHK: 6996 | $279.47M | HK$3.19 | -4.06% |
Figures last refreshed Oct 11, 2026.